moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clini

Moleculin Biotech, Inc.

Sold all MBRX

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Mitchell

Sold 50% of MBRX

New position in MBRX

Tyler Caruso

Lemuel

Bought 100% more MBRX

Bought 122% more MBRX